Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment

Journal of Cerebral Blood Flow and Metabolism

Volumn 31, Issue 6, 2011, Pages 1461-1474

  Kanazawa, Masato ^a   Igarashi, Hironaka ^a   Kawamura, Kunio ^a   Takahashi, Tetsuya ^a   Kakita, Akiyoshi ^a   Takahashi, Hitoshi ^a   Nakada, Tsutomu ^a   Nishizawa, Masatoyo ^a   Shimohata, Takayoshi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

hemorrhagic transformation; ischemia; rat; tPA; VEGF

Indexed keywords

GELATINASE B; NEUTRALIZING ANTIBODY; PLACEBO; RB 222; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; THERAPY DELAY; THROMBOEMBOLISM;

ANIMALS; ANTIBODIES, NEUTRALIZING; BLOOD-BRAIN BARRIER; HEMORRHAGE; MALE; MATRIX METALLOPROTEINASE 9; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957928847     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2011.9     Document Type: Article

References (49)

1. Al Ahmad A, Gassmann M, Ogunshola OO (2009) Maintaining blood-brain barrier integrity: pericytes perform better than astrocytes during prolonged oxygen deprivation. J Cell Physiol 218:612-22
2. Andersen M, Overgaard K, Meden P, Boysen G (1999) Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 30: 1464-71 (Pubitemid 29296078)
3. Asahi M, Asahi K, Wang X, Lo EH (2000) Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 20:452-7 (Pubitemid 30164888)
4. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-44
5. Busch E, Kruger K, Hossmann KA (1997) Improved model of thromboembolic stroke and rt-PA induced reperfu-sion in the rat. Brain Res 778:16-24 (Pubitemid 28039884)
6. Chodobski A, Chung I, Koźniewska E, Ivanenko T, Chang W, Harrington JF, Duncan JA, Szmydynger-Chodobska J (2003) Early neutrophilic expression of vascular en- dothelial growth factor after traumatic brain injury. Neuroscience 122:853-67 (Pubitemid 37485840)
7. Chi OZ, Hunter C, Liu X, Weiss HR (2005) Effects of VEGF and nitric oxide synthase inhibition on blood-brain barrier disruption in the ischemic and non-ischemic cerebral cortex. Neurol Res 27:864-8 (Pubitemid 41790273)
8. Chi OZ, Hunter C, Liu X, Weiss HR (2007) Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia. Exp Neurol 204:283-7 (Pubitemid 46330278)
9. Fagan SC, Nagaraja TN, Fenstermacher JD, Zheng J, Johnson M, Knight RA (2003) Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model. Neurol Res 25:377-82 (Pubitemid 36818724)
10. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-76 (Pubitemid 36749215)
11. Foster KA, Regan HK, Danziger AP, Detwiler T, Kwon N, Rickert K, Lynch JJ, Regan CP (2009) Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor. Neurosci Res 63:10-6
12. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, Wang X, Rosenberg GA, Lo EH, Moskowitz MA (2004) Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113:1447-55 (Pubitemid 39071700)
13. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317-29
14. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2:289-300 (Pubitemid 41043963)
15. Ijichi A, Sakuma S, Tofilon PJ (1995) Hypoxia-induced vascular endothelial growth factor expression in normal rat astrocyte cultures. Glia 14:87-93
16. Ishikawa K, Honda S, Tsukahara Y, Negi A (2009) Preferable use of intravitreal bevacizumab as a pretreat-ment of vitrectomy for severe proliferative diabetic retinopathy. Eye 23:108-11
17. Jiang Q, Zhang RL, Zhang ZG, Ewing JR, Jiang P, Divine GW, Knight RA, Chopp M (2000) Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke. J Cereb Blood Flow Metab 20:21-7 (Pubitemid 30019826)
18. Lee SR, Lee SR, Guo SZ, Scannevin RH, Magliaro BC, Rhodes KJ, Wang X, Lo EH (2007) Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci Lett 417:1-5 (Pubitemid 46533879)
19. Lin CW, Hou WC, Shen SC, Juan SH, Ko CH, Wang LM, Chen YC (2008) Quercetin inhibition of tumor invasion via suppressing PKCd/ERK/AP-1-dependent matrix me-talloproteinase-9 activation in breast carcinoma cells. Carcinogenesis 29:1807-15
20. Lo EH (2008) A new penumbra: transitioning from injury into repair after stroke. Nat Med 14:497-500 (Pubitemid 351655209)
21. Kanazawa M, Kakita A, Igarashi H, Takahashi T, Kawamura K, Takahashi H, Nakada T, Nishizawa M, Shimohata T (2011) Biochemical and histopathological alterations in TAR DNA-binding protein-43 after acute ischemic stroke. J Neurochem (in press)
22. Kimura R, Nakase H, Tamaki R, Sakaki T (2005) Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction. Stroke 36:1259-63 (Pubitemid 40803474)
23. Kovács Z, Ikezaki K, Samoto K, Inamura T, Fukui M (1996) VEGF and flt. Expression time kinetics in rat brain infarct. Stroke 27:1865-72
24. Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Varticovski L, Isner JM (1995) Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270:31189-95 (Pubitemid 26012206)
25. Ogunshola OO, Antic A, Donoghue MJ, Fan SY, Kim H, Stewart WB, Madri JA, Ment LR (2002) Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J Biol Chem 277:11410-5 (Pubitemid 34952908)
26. Okubo S, Igarashi H, Kanamatsu T, Hasegawa D, Orima H, Katayama Y (2007) FK-506 extended the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in an embolic rat stroke model. Brain Res 1143:221-7 (Pubitemid 46440820)
27. Petito CK, Levy DE (1980) Theimportance of cerebral arterioles in alterations of the blood-brain barrier. Lab Invest 43:262-8 (Pubitemid 10061706)
28. Shimohata T, Zhao H, Sung JH, Sun G, Mochly-Rosen D, Steinberg GK (2007) Suppression of dPKC activation after focal cerebral ischemia contributes to the protective effect of hypothermia. J Cereb Blood Flow Metab 27:1463-75 (Pubitemid 47106606)
29. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH (1997) Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741-7 (Pubitemid 27509365)
30. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK (1996) Flk-1 as a target for tumor growth inhibition. Cancer Res 56:3540-5 (Pubitemid 26251650)
31. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA (2008) Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14:731-7
32. Sumii T, Lo EH (2002) Involvement of matrix metallopro-teinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33:831-6 (Pubitemid 34204013)
33. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, Greenberg DA (2003) VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111:1843-51 (Pubitemid 38057729)
34. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR (1990) A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10:290-3 (Pubitemid 20096202)
35. The National Institute of Neurological Disorders and Stroke rt-PA stroke Study Group (1995) Tissue plasmi-nogen activator for acute ischemic stroke. N Engl J Med 333:1581-7
36. Valable S, Montaner J, Bellail A, Berezowski V, Brillault J, Cecchelli R, Divoux D, Mackenzie ET, Bernaudin M, Roussel S, Petit E (2005) VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1. J Cereb Blood Flow Metab 25:1491-504 (Pubitemid 41541959)
37. van Bruggen N, Thibodeaux H, Palmer JT, Lee WP, Fu L, Cairns B, Tumas D, Gerlai R, Williams SP, van Lookeren Campagne M, Ferrara N (1999) VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest 104:1613-20 (Pubitemid 30002373)
38. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y (2008) Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115:1571-80
39. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH (2004) Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35:2726-30 (Pubitemid 39458380)
40. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4:228-31 (Pubitemid 28138083)
41. Warner-Schmidt JL, Duman RS (2007) VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 104:4647-52 (Pubitemid 47186279)
42. Weis S, Cui J, Barnes L, Cheresh D (2004) Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167:223-9 (Pubitemid 39435066)
43. Yepes M, Bugge TH, Strickland DK, Lawrence DA (2003) Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112:1533-40 (Pubitemid 38056279)
44. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH (2006) Role of matrix metalloprotei-nases in delayed cortical responses after stroke. Nat Med 12:441-5
45. Zhang L, Chopp M, Jia L, Cui Y, Lu M, Zhang ZG (2009) Atorvastatin extends the therapeutic window for tPA to 6 hours after the onset of embolic stroke in rats. J Cereb Blood Flow Metab 29:1816-24
46. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, Bruggen N, Chopp M (2000) VEGF enhances angiogen-esis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106:829-38
47. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, Zhang R, Goussev A, Powers C, Yeich T, Chopp M (2002a) Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angio-genesis after focal cerebral ischemia. J Cereb Blood Flow Metab 22:379-92 (Pubitemid 34273594)
48. Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M (2002b) Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106:740-5 (Pubitemid 34851936)
49. Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, Schmökel H, Bezuidenhout D, Djonov V, Zilla P, Hubbell JA (2003) Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J 17:2260-2 (Pubitemid 39561459)